Drug Trial Radar · NCT07257185
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 17, 2026
Primary completion
Aug 31, 2027
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
Conditions
- Thyroid Eye Disease (TED)
Interventions
MHB018A injectionDrug
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
MHB018A injection PlaceboDrug
6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate at Week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.